logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Zydus Lifesciences Ltd

Zydus Lifesciences

Large Cap•26,921 Employees•IPO 1995
Current Price
₹864.25
1.05 (0.12%)Updated
NSE :ZYDUSLIFE
BSE :532321
Sector :Pharmaceuticals
Today's Range
835.5
₹864.25
indicator
866
52 Week Range
52W Low₹795.00
52W High₹1059.05
₹864.25
indicator
Downside8.71%
Upside22.54%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹93,078.67 Cr
Market Cap
Total market value of company
P/E Ratio
18.92
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.90
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹48.89
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
9.86%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
24.30%
ROCE
Return on Capital Employed. >15% is good
Net Margin
20.09%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
31.38%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
10.27%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
16.90%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
40.90%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.13
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹238.05
Book Value
Net asset value per share
Dividend Yield
1.19%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
75.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust profitability: OPM 29.90%, ROE 21.20%, ROCE 24.30% demonstrate efficient operations.
  • •High promoter holding (75%) and low debt-to-equity (0.13) signal strong confidence.

Weaknesses

5 points
  • •Stock exhibits volatility, with a 52-week low of ₹795, indicating market sensitivity.
  • •Substantial absolute debt (₹3213 Cr) requires careful management despite low debt-to-equity.

Opportunities

5 points
  • •Capitalize on global healthcare demand, demographic shifts, and increasing R&D investments.
  • •Market expansion into emerging economies and diversification into new therapeutic areas.

Threats

4 points
  • •Intense competition in the pharmaceutical sector could pressure pricing and market share.
  • •Evolving regulatory policies and drug pricing controls pose significant threats.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹936.00+₹71.75+8.30%
R3₹905.50+₹41.25+4.77%
R2₹885.75+₹21.50+2.49%
R1₹875.00+₹10.75+1.24%
PIVOT₹855.25-9.00-1.04%
CURRENT₹864.25--
S1₹783.50-₹80.75-9.34%
S2₹814.00-₹50.25-5.81%
S3₹824.75-₹39.50-4.57%
S4₹844.50-₹19.75-2.29%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.01M
(02 Apr 2026)
+52.1% vs avg
Delivery %
48.9%
(02 Apr 2026)
-1.8% vs avg
Avg Volume (20D)
6.66L
(04 Mar - 02 Apr)
20-day average
Avg Delivery %
50.7%
(04 Mar - 02 Apr)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Abbott India Ltd
1.79 %

Peer Comparison

Company Name
ABBOTINDIA
Abbott India Ltd
ALKEM
Alkem Laboratories Ltd
AUROPHARMA
Aurobindo Pharma Ltd
CIPLA
Cipla Ltd
DRREDDY
Dr Reddys Laboratories Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
LAURUSLABS
Laurus Labs Ltd
LUPIN
Lupin Ltd
MANKIND
Mankind Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd

About

ZYDUSLIFE

Zydus Lifesciences Ltd

Zydus Lifesciences Limited is a global pharmaceutical company with a diverse portfolio spanning research, development, manufacturing, marketing, and distribution of a wide range of healthcare products. Its operations extend across India, the United States, and other international markets, solidifying its position as a significant player in the industry.

The company's business is structured into two primary segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment focuses on the production and sale of finished dosage forms, including generic drugs, branded generics, and specialty formulations such as biosimilars and vaccines. They also manufacture active pharmaceutical ingredients (APIs) and cater to various therapeutic areas, encompassing pain management, neurology, metabolic disorders, and liver diseases. A strong pipeline of biological products is under development, targeting oncology, autoimmune diseases, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses.

Complementing its pharmaceutical offerings, the Consumer Products segment encompasses a portfolio of well-known brands such as Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil. These brands cater to various consumer wellness needs, demonstrating Zydus Lifesciences' commitment to holistic healthcare solutions.

Beyond its core pharmaceutical and consumer product businesses, Zydus Lifesciences also engages in other activities, including investments in related sectors, animal health and veterinary products, pharmacy retail ventures, and manpower supply and administration. This diversification strategy reflects a commitment to expanding its reach and influence within the broader healthcare ecosystem.

Founded in 1952 and headquartered in Ahmedabad, India, the company, formerly known as Cadila Healthcare Limited, rebranded to Zydus Lifesciences Limited in 2022. It operates as a subsidiary of Zydus Family Trust, reflecting its long-standing commitment to family-led stewardship and its history in the pharmaceutical industry.

COMPANY FACTS - ZYDUSLIFE

Registered Address

Zydus Corporate Park, Scheme No. 63, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Sarkhej-Gandhinagar Highway

Ahmedabad

GUJARAT

IN

Tel: 917926868100

Website:https://www.zyduslife.com/zyduslife/

Investor Relations:http://www.zyduslife.com/financials#6
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 26,921

IPO Date: 15/05/1995

MANAGEMENT - ZYDUSLIFE

Shri. Pankaj Patel

Non-Executive Chairman of the Board

Mr. Nitin Parekh

Chief Financial Officer

Mr. Dhaval Soni

Company Secretary, Compliance Officer

Dr. Sharvil Patel

Managing Director, Executive Director

Mr. Ganesh Nayak

Executive Director

Mr. Mukesh Patel

Non-Executive Director

Shri. Apurva Diwanji

Non-Executive Independent Director

Ms. Upasana Konidela

Non-Executive Independent Director

Mr. Akhil Monappa

Non-Executive Independent Director

Ms. Shelina Parikh

Non-Executive Independent Director

Shri. Bhadresh Shah

Non-Executive Independent Director

Mr. Arvind Bothra

Head - Investor Relations

Investor Questions Answered

Zydus Lifesciences Ltd (ZYDUSLIFE) Stock FAQs

Get answers to the most common questions about Zydus Lifesciences Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Zydus Lifesciences Ltd (ZYDUSLIFE) is ₹864.25. Today, the stock has gained by ₹1.05 (0.12%), trading in a range of ₹835.5 to ₹866. The stock opened at ₹860 with a trading volume of 10,13,019 shares.
Zydus Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹93,078.67 crores, P/E ratio of 18.92, ROE of 9.86%, and ROCE of 24.30%. The dividend yield stands at 1.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Zydus Lifesciences Ltd (ZYDUSLIFE) is ₹1,059.05, while the 52-week low is ₹795. Currently trading at ₹864.25, the stock is 26.2% away from its 52-week low and 18.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Zydus Lifesciences Ltd stock at ₹864.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 18.92 and P/B ratio of N/A. Today's performance shows a gain of 0.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Zydus Lifesciences Ltd offers a dividend yield of 1.19%, which means for every ₹100 invested at the current price of ₹864.25, you can expect to receive approximately ₹1.19 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Zydus Lifesciences Ltd's key financial metrics include: P/E Ratio: 18.92, P/B Ratio: N/A, ROE: 9.86%, ROCE: 24.30%, Dividend Yield: 1.19%, EPS: ₹48.89, Book Value: ₹238.05, Debt-to-Equity: 0.13, and Current Ratio: N/A. The company's market cap stands at ₹93,078.67 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Zydus Lifesciences Ltd stock opened at ₹860 and is currently trading at ₹864.25, showing a gain of ₹1.05 (0.12%). The intraday high is ₹866 and low is ₹835.5. The trading volume stands at 10,13,019 shares, indicating strong market participation today.
Zydus Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 18.92, which means investors are willing to pay ₹18.92 for every ₹1 of earnings. With an EPS of ₹48.89, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Zydus Lifesciences Ltd has a market capitalization of ₹93,078.67 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹864.25) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Zydus Lifesciences Ltd has a book value of ₹238.05 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹864.25, which is 263.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Zydus Lifesciences Ltd has a Return on Equity (ROE) of 9.86% and Return on Capital Employed (ROCE) of 24.30%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Zydus Lifesciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Zydus Lifesciences Ltd has a debt-to-equity ratio of 0.13, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Zydus Lifesciences Ltd has an Earnings Per Share (EPS) of ₹48.89, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹864.25 and P/E ratio of 18.92, investors are paying 18.92 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Zydus Lifesciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Zydus Lifesciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Zydus Lifesciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (18.92), ROE (9.86%), debt-to-equity (0.13), and growth rates. 2) Technical Analysis - Check 52-week range (₹795.00 - ₹1059.05), moving averages, and chart patterns. 3) Valuation - Compare current price (₹864.25) with book value (₹238.05) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Zydus Lifesciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹864.25 is 86325x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Zydus Lifesciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹795.00 - ₹1059.05). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.13 indicates leverage. 4) Liquidity Risk - Based on trading volume of 10,13,019 shares. 5) Valuation Risk - P/E of 18.92 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Zydus Lifesciences Ltd operates in the industry with key metrics: P/E ratio of 18.92, ROE of 9.86%, market cap of ₹93,078.67 crores, and dividend yield of 1.19%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.13), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Zydus Lifesciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹864.25, with a 52-week range of ₹795.00 to ₹1059.05. Based on fundamentals like P/E (18.92), ROE (9.86%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Zydus Lifesciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹864.25. 2) Fundamental Deterioration - Declining ROE (currently 9.86%), increasing debt (D/E: 0.13), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Zydus Lifesciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.19%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.